admin
Conservative doctors like Chauncey Crandall have been right to call attention to a striking new study showing that artificial intelligence can pull double duty from routine mammograms — screening for breast cancer while also flagging calcium buildup in breast arteries that signals heart disease risk. This isn’t speculative alarmism; researchers presented data showing AI tools can quantify breast arterial calcification on standard mammograms and translate that into a cardiovascular risk signal, a development clinicians are rightly excited about.
Breast arterial calcification, long treated as an incidental footnote on imaging reports, now tracks with meaningful increases in heart attacks, strokes, heart failure and death when measured rigorously. Large retrospective analyses using AI to grade BAC severity found stepwise increases in risk from mild to severe calcification, demonstrating that what was once ignored could save lives if acted upon.
One of the practical beauties of this advance is that it leverages scans millions of women already receive — there’s no extra radiation, no new appointment, and no expensive new gadget required for the initial screening. Using AI to opportunistically screen for cardiovascular risk during a breast cancer check is commonsense medicine: efficient, cost-conscious, and focused on prevention rather than bureaucratic box-checking.
Private-sector innovators have already been building these tools, and early results from commercial systems show they can reliably flag arterial calcification and provide clinicians with actionable information. Companies and academic teams presented data at cardiology meetings confirming that AI suites can detect and quantify BAC on mammograms, which means the technology is ready to move from research into routine care if regulators and providers let it.
As conservatives, we should celebrate technology that empowers doctors and patients rather than expanding government surveillance or one-size-fits-all mandates. This is an opportunity to return power to clinicians and families: give women their results, let their physicians interpret the risk, and allow patients to choose preventive steps — lifestyle changes, statins, or follow-up testing — without another layer of top-down interference.
That said, prudent implementation matters. We should demand transparency about algorithms, protect patient privacy, and avoid letting Big Tech dictate clinical decisions; but we should never let fear of innovation keep lifesaving tools on the shelf. Congress and state regulators should clear the path for responsible adoption so that every hardworking American woman gets the full benefit of screenings she already volunteers for, not an excuse for bureaucratic delay.
